Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Finding Key Collaborators in the Data

Posted on August 23rd, 2017 by in Pharma R&D

banner-Data-driven-evaluation-img-940x400

R&D is no longer a solely in-house process where Big Pharma researchers work diligently in secret to come up with the next blockbuster drug. Rising costs, patient needs, global trends, healthcare reform, changes in clinical development models and many other factors have altered the R&D landscape. In today’s environment, pharmaceutical firms must reach outward in order to innovate.To drive successful drug discovery and development, pharma companies have become increasingly reliant on fruitful collaborations with a variety of partners, including innovative biotech companies, contract research organizations (CROs), academic institutions and individual experts as well. Working with these outside partners supercharges internal R&D and creates shared risks and rewards among collaborators.

But the question then becomes: how do pharma companies find the right partners? The new white paper “Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships” suggests that the typical methods of networking, whether it’s exchanging business cards at conferences or calling up the author of a journal article you recently read, are not good enough anymore.

To locate the collaborators who will best suit their needs, companies must look into the data. Just as pharmaceutical R&D relies on big data for understanding diseases and developing drugs, now they must turn to sophisticated data analysis to help identify and qualify potential partners.

Read the white paper to find out more.


All opinions shared in this post are the author’s own.

R&D Solutions for Pharma & Life Sciences

We're happy to discuss your needs and show you how Elsevier's Solution can help.

Contact Sales